NextCure, Inc. Files 8-K Report
Ticker: NXTC · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: NCUX
TL;DR
NextCure filed an 8-K, but no new info released.
AI Summary
On January 10, 2025, NextCure, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial updates detailed in the provided text. The company is incorporated in Delaware and headquartered in Beltsville, Maryland.
Why It Matters
This 8-K filing indicates NextCure, Inc. has submitted a regulatory report, but the provided text does not disclose specific material events or financial information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission without disclosure of new material events or financial changes.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- Beltsville, Maryland (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as of January 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported is dated January 10, 2025.
Where is NextCure, Inc. headquartered?
NextCure, Inc.'s principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
What is NextCure, Inc.'s IRS Employer Identification Number?
NextCure, Inc.'s IRS Employer Identification Number is 47-5231247.
In which state is NextCure, Inc. incorporated?
NextCure, Inc. is incorporated in Delaware.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-10 08:15:41
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo
Filing Documents
- nxtc-20250110x8k.htm (8-K) — 48KB
- nxtc-20250110xex99d1.htm (EX-99.1) — 11KB
- nxtc-20250110xex99d1001.jpg (GRAPHIC) — 6KB
- 0001558370-25-000099.txt ( ) — 198KB
- nxtc-20250110.xsd (EX-101.SCH) — 4KB
- nxtc-20250110_def.xml (EX-101.DEF) — 3KB
- nxtc-20250110_lab.xml (EX-101.LAB) — 17KB
- nxtc-20250110_pre.xml (EX-101.PRE) — 11KB
- nxtc-20250110x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On January 10, 2025, NextCure, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 10, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: January 10, 2025 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer